RESEARCH ARTICLE

Osteoprotective Effect of Echinocystic Acid, a Triterpone Component from *Eclipta prostrata*, in Ovariectomy-Induced Osteoporotic Rats

Ya-ting Deng[1☯], Wen-bo Kang[2☯], Jian-ning Zhao[2]*, Gang Liu[2]*, Ming-gao Zhao[1]*

1 Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, Xi'an, China,
2 Department of Orthopedics, Jinling Hospital, Clinical School of Nanjing, Second Military Medical University, Nanjing, China

☯ These authors contributed equally to this work.
* jnzhao2002@163.com (JNZ); liugene@hotmail.com (GL); minggao@fmmu.edu.cn (MGZ)

Abstract

Echinocystic acid (EA) is a natural triterpone enriched in various herbs and has been used for medicinal purposes in China. In the present study, we systematically examined the effects of EA on ovariectomy-induced osteoporosis in rats for the first time. Three-month-old female ovariectomy (OVX) Sprague–Dawley rats were used to evaluate the osteoprotective effect of EA. Results showed that administration of EA (5 or 15 mg/kg/day) for 12 weeks prevented lower levels of maximum stress and Young's modulus of femur induced by OVX. EA also recovered bone metabolic biomarkers levels in OVX rats, including osteocalcin, alkaline phosphatese, deoxypyridinoline, and urinary calcium and phosphorus. EA (5 and 15 mg/kg/day) could prevent the alteration of total bone mineral density in the femur caused by OVX. However, only high dose (15 mg/kg/day) of EA significantly improved trabecular architecture, as evidenced by higher levels of bone volume/tissue volume, trabecula number, and trabecula thickness, and lower levels of trabecula separation and structure model index compared with OVX rats. In addition, EA treatment decresed the serum levels of IL-1β and TNF-α in OVX rats. In conclusion, EA could prevent reduction of bone mass and strength and improve the cancellous bone structure and biochemical properties in OVX rats. Hence, EA may serve as a new candidate or a leading compound for anti-osteoporosis.

Introduction

Osteoporosis, characterized by low bone mineral density (BMD) and fragility of the bone, is a worldwide health problem for the aging population. Approximately 40 percent of women over the age of 50 suffer from osteoporotic fracture[1]. Recent studies have suggested that pro-inflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α) play an important role in postmenopausal osteoporosis[2,3].

Present drugs offer specific and clearly targeted therapeutic effects on the improvement of bone quality; however, side effects remain the clinical problems for patients[4,5,6] In recent years, there is a growing interest in developing anti-osteoporosis agents from plants. Flavonoids derived from food and herbs have been shown to have anti-osteoporotic effects in animal models and clinical trials [7,8,9,10,11,12]. However, other kinds of phytochemicals received less attention for their potential role in preventing osteopenia. Recently, several triterpenoids, including oleanolic acid, ursolic acid, and their derivatives, have been reported to prevent bone loss by stimulating the osteoblastic differentiation of bone mesenchymal stem cells and inhibiting the formation of osteoclasts [13,14,15].

Echinocystic acid (EA) is one of the triterpenes sharing a similar structure with oleanolic acid. Multiple pharmacological effects of EA have been found including anti-inflammation [16,17,18], anti-viral [19], cytotoxic activity to cancer cells [20], and protective effects against acute myocardial ischemia [21]. EA is a natural triterpone enriched in various herbs, including *Eclipta prostrata*. A previous study has demonstrated that *Eclipta prostrate* has beneficial effects on ovariectomy (OVX)-induced osteoporotic rats [22]. Based on the above researches, it is reasonable to hypotesize that EA might take a active role in estrogen defciency-related osteoporosis. However, little is known on the anti-osteoporotic effects of EA on bone loss. Therefore, the purpose of this study is to evaluate the effects of EA on osteoporosis induced by OVX in rats, and it has been found that EA reversed the reduction of bone mass and strength and improved the cancellous bone structure and biochemical properties in OVX rats.

Materials and Methods

Drugs and reagents

17β-estradiol (E2) was purchased from the Xi'an Hualian Pharmaceutical. The kits for measurement of calcium, inorganic phosphorus and alkaline phosphatase activity were obtained from ZhongSheng BeiKong Bio-technology and Science (Beijing, China). Enzyme-Linked Immuno Sorbent Assay (ELISA) kits for measurement of deoxypyridinoline (DPD), osteocalcin (also called bone Gla Protein, BGP), IL-1β and TNF-α were purchased from Elabscience Biotechnology Co., Ltd (Wuhan, China).

Animals and treatments

Three-month-old female Sprague–Dawley rats (220–250 g) were purchased from the Experimental Animal Center of the Fourth Military Medical University. Rats were given standard food and water per day under controlled conditions of temperature (23 ± 2°C) and relative humidity (50% ± 5%) and light-dark cycle (light on from 8 a.m. to 8 p.m.) throughout the experimental period [23]. After a 1-week adaptation period, 10 rats were sham-operated and treated with vehicle as aging control (sham). The remaining rats were bilaterally ovariectomized and randomly divided into five groups with 10 rats per group. The operation was performed under pentobarbital sodium (35 mg/kg, i.p.) anesthesia. After operation rats were kept at the incubator to maintain body temperature until they recovered; the weight and daily food consumption were monitored in the following weeks. Four weeks after surgery, the OVX rats were treated with vehicle, E2 (25 µg/kg/day, ig), or EA (1, 5, and 15 mg/kg/day, ig) for 12 weeks. Body weight was recorded once a week throughout the experiment. There were no any unintended deaths during this study. To minimize the suffering of the animals, animals were first anesthetized with 2.5% isoflurane before sacrifice. Before anesthesia, urine samples were collected individually for 24 h in metabolic cages without providing food. Blood samples were taken from abdominal aorta under isoflurane anesthesia. Uteri were removed and immediately weighed. Femurs were dissected and stored in physiological saline at −80°C until examination

for biomechanical testing and structural analysis. This study was approved by the institutional ethics committee of the Fourth Military Medical University.

Measurements of bone biomechanical strength

The mechanical properties of the left femurs were determined by a three-point bending test [24,25]. The biomechanical parameters of the left femoral diaphysis was measured by a CMT4204 material testing machine (Shenzhen Skyan Power Equipment Co. Ltd., Shenzhen, China). Briefly, the left femurs were thawed at room temperature for at least 1 h, and then placed in the material test machine with 20 mm distance between two support points. The loading speed was set at 2 mm/min. The ultimate load (maximum load), energy absorbed to failure, elastic modulus and ultimate stress (maximum stress) were obtained, and the bone load-displacement curves were plotted with the software simultaneously [25].

Assay for serum and urine chemistry

Serum calcium (S-Ca), phosphorus (S-P), and alkaline phosphatase (ALP) concentrations were measured by commercial kits and analyzed by a Cobas Integra 400 Plus automatic biochemical analyzer (Roche Diagnostics, Basel, Switzerland). Urine calcium (U-Ca), phosphorus (U-P), and creatinine (Cr) concentrations were evaluated by the same method. Serum levels of osteo-calcin (OC),IL-1β and TNF-α were determined by ELISA kits. Urinary deoxypyridinoline (DPD) level was also assayed using ELISA kit. The urinary excretion of Ca and DPD were expressed as the ratio to Cr concentration (Ca/Cr and DPD/Cr) [25].

Bone microarchitecture assessment by micro-computed tomography

Bone microarchitecture in distal femur was scanned by eXplore Locus SP Pre-Clinical Specimen Micro-Computed Tomography (GE Healthcare, USA). The reconstruction and 3D quantitative analyses were performed by the desktop micro-computed tomography system. In the femora, the scanning regions were confined to the distal metaphysis, extending proximally 2.0 mm from the proximal tip of the primary spongiosa. The following 3D indices in the defined region of interest were analyzed, including relative bone volume over total volume (BV/TV, %), trabecular separation (Tb.Sp), trabecular number (Tb.N), trabecular thickness (Tb.Th), structure model index (SMI) and BMD[25,26]. The operator performing the scan analysis was blinded to the treatments revelant with the specimens.

Statistical analysis

Results were expressed as mean ± SEM. Data were evaluated using one-way analysis of variance (ANOVA) for *post hoc* comparisons (SPSS 13.0). The data that passed the homogeneity test were analyzed by the one-way ANOVA Least Significant Difference (LSD) test. Data that did not pass the homogeneity test were analyzed by the one-way ANOVA Dunnett's T3 test [27]. In all cases, $p < 0.05$ was considered statistically significant.

Results

EA had no effects on body and uterine weight in OVX rats

The body weight of OVX rats was markedly increased from the 5th week after operation compared with the sham rats. E2 treatment could prevent increase in body weight, whereas EA (1, 5, and 15 mg/kg/day) had no effects on the body weight in OVX rats (Fig 1A). As predicted, the uterine weight of OVX significantly decreased, indicating the success of the surgical procedure. E2 treatment could prevent the decrease of uterine weight, whereas EA did not affect the

Fig 1. Effects of EA on body weight and uterus index. (A) Effects of E2 and EA on body weight. (B) The uterus index was represented as uterus weight divided by body weight. E2 (25 µg/kg/day); EA-L (1 mg/kg/day); EA-M (5 mg/kg/day); EA-H (15 mg/kg/day). n = 10; ** $p < 0.01$ vs OVX; ## $p < 0.01$ vs Sham.

doi:10.1371/journal.pone.0136572.g001

uterine weight in the OVX rats ($F_{(5, 54)} = 19.245$, $p < 0.01$, Dunnett's T3 test; $p = 0.001$, OVX vs. Sham; $p = 0.001$, E2 vs OVX; Fig 1B).

EA improves biomechanical properties of bone

Three-point bending test was performed in the left femur to determine the bone strength. The extrinsic biomechanical property of the bone was evaluated by ultimate load and energy absorbed to failure, while elastic modulus and ultimate stress were assayed as intrinsic biomechanical parameters. As shown in Table 1, OVX induced a slight decrease in the levels of the maximum load and energy, but resulted in a significant decrease in the elastic modulus and maximum stress ($F_{(5, 54)} = 16.319$, $p < 0.01$, Dunnett's T3 test; $p = 0.000$, OVX vs Sham for elastic modulus; $F_{(5, 54)} = 2.827$, $p > 0.01$, LSD test; $p = 0.005$, OVX vs Sham for maximum stress).The E2 and EA administration significantly prevented the decrease of elastic modulus induced by OVX ($p = 0.009$, E2 vs OVX; $p = 0.006$, EA-M vs OVX; $p = 0.000$, EA-H vs OVX; Table 1). As predicted, maximum stress was also significantly higher compared with the OVX group after EA and E2 treatment ($p = 0.046$, E2 vs OVX; $p = 0.049$, EA-M vs OVX; $p = 0.045$, EA-H vs OVX; Table 1). Lower dose of EA (1 mg/kg) had marginal effects on the biomechanical properties ($p = 0.362$, EA-L vs OVX for elastic modulus; $p = 0.139$, EA-L vs OVX for maximum stress; Table 1).

Table 1. Effects of EA on bone biomechanical parameters in femoral diaphysis of OVX rats.

Parameters	Sham	OVX	E2	EA-L	EA-M	EA-H
Elastic modulus (MPa)	6336±203	4679±112##	6123±227**	5100±359	5844±254*	6374±157**
Maximum stress (MPa)	165±18	137±8##	152±3**	137±3	150±1*	155±20**
Maximum load (N)	125±5	111±5	113±3	123±13	123±8	123±9
Energy (N*mm)	54±1	51±1	54±1	51±1	51±1	54±19

EA-L: EA (1 mg/kg); EA-M: EA (5 mg/kg); EA-H: EA (15 mg/kg); n = 10

*$p < 0.05$

**$p < 0.01$ vs OVX

##$p < 0.01$ vs sham.

doi:10.1371/journal.pone.0136572.t001

EA prevented alterations of bone metabolic biomarkers in OVX rats

In OVX group, the U-Ca and U-P levels were higher compared with the sham group; however, the levels of S-Ca and S-P did not show changes among the groups (Table 2). Treatment with EA or E2 reversed the elevated U-Ca levels in OVX rats ($F_{(5, 54)} = 18.680$, $p < 0.01$, Dunnett's T3 test; $p = 0.000$, E2 vs OVX; $p = 1.000$, EA-L vs OVX; $p = 0.002$, EA-M vs OVX; $p = 0.000$, EA-H vs OVX). Only high dose of EA (15 mg/kg/day) recovered the U-P levels in OVX rats ($F_{(5, 54)} = 1.068$, $p > 0.01$, LSD test; $p = 0.032$, EA-H vs OVX; Table 2). The serum ALP level is an early phase marker of osteoblast hyperactivity and bone formation during the matrix maturation phase [28,29]. Osteocalcin, one of the major non-collagenous proteins secreted solely by osteoblasts, is a late phase osteoblastic differentiation marker[30,31]. OVX induced higher levels of serum ALP and osteocalcin sixteen weeks after operation. These alterations were recovered by treatment with EA or E2 in the OVX rats ($F_{(5, 54)} = 29.742$, $p < 0.01$, Dunnett's T3 test; $p = 0.001$, E2 vs OVX; $p = 1.000$, EA-L vs OVX; $p = 0.054$, EA-M vs OVX; $p = 0.000$, EA-H vs OVX for ALP; Fig 2A; $F_{(5, 54)} = 6.777$, $p < 0.01$, Dunnett's T3 test; $p = 0.011$, E2 vs OVX; $p = 1.000$, EA-L vs OVX; $p = 0.787$, EA-M vs OVX; $p = 0.017$, EA-H vs OVX for OC; Fig 2B). In addition, the urinary DPD/Cr ratio (a bone resorption marker) was much more higher in OVX rats. Treatment with EA or E2 prevented this alteration in the OVX rats ($F_{(5, 54)} = 15.713$,

Table 2. Effects of EA on biochemical parameters in serum and urine of OVX rats.

| Group	S-Ca (mM)	S-P (mM)	U-Ca/Cr	U-P/Cr
Sham	2.61±0.04	3.3±0.2	0.39±0.01	3.7±0.2
OVX	2.56±0.06	3.4±0.1	1.05±0.06##	4.5±0.1##
E2	2.62±0.09	3.2±0.2	0.39±0.01**	4.0±0.2**
EA-L	2.60±0.03	3.4±0.1	1.02±0.04	4.5±0.1
EA-M	2.59±0.06	3.2±0.2	0.41±0.01**	4.3±0.1
EA-H	2.60±0.11	3.3±0.2	0.39±0.02**	4.2±0.2*

EA-L: EA (1 mg/kg); EA-M: EA (5 mg/kg); EA-H: EA (15 mg/kg); n = 10; n = 10

*$p < 0.05$

**$p < 0.01$ vs OVX

##$p < 0.01$ vs sham.

doi:10.1371/journal.pone.0136572.t002

Fig 2. Effects of EA on bone formation and resorption parameters. (A) Effects of E2 and EA on serum alkaline phosphatase (ALP). **(B)** Effects of E2 and EA on serum osteocalcin (OC). **(C)** Effects of E2 and EA on urinary deoxypyridinoline (DPD/Cr). E2 (25 μg/kg/day); EA-L (1 mg/kg/day); EA-M (5 mg/kg/day), EA-H (15 mg/kg/day). n = 10; * $p < 0.05$, ** $p < 0.01$ vs OVX; ## $p < 0.01$ vs Sham.

doi:10.1371/journal.pone.0136572.g002

$p > 0.01$, LSD test; $p = 0.001$, E2 vs OVX; $p = 0.600$, EA-L vs OVX; $p = 0.000$, EA-M vs OVX; $p = 0.000$, EA-H vs OVX; Fig 2C). The low dose of EA (1 mg/kg) had marginal effects on the above parameters.

EA improves BMD and trabecular architecture in OVX rats

Because the low dose of EA (1 mg/kg) had marginal effects on the bone metabolic biomarkers, Micro-computed tomography analysis was only performed in the rats treated with middle and high dose of EA. The BMD of the right femur was lower in OVX rats. Treatment with EA or E2 prevented this alteration in the OVX rats ($F_{(4, 45)} = 10.831$, $p > 0.01$, LSD test; Fig 3). Further three-dimensional images of tibial metaphysis showed differences in the trabecular architecture among groups (Fig 4). Micro-computed tomography analysis revealed that levels of BV/TV, Tb.N, and Tb.Th were lower in OVX rats as compared with the shams. By contrast, SMI and Tb.Sp were higher. The EA (15 mg/kg) or E2 treatment prevented the OVX-induced deterioration of microstructure in trabecular, as shown by elevated levels of trabecular BV/TV, Tb.N, and Tb.Th in OVX rats ($F_{(4, 45)} = 28.319$, $p < 0.01$, Dunnett's T3 test for BV/TV; $F_{(4, 45)} = 30.417$, $p < 0.01$, Dunnett's T3 test for Tb.N; $F_{(4, 45)} = 8.526$, $p > 0.01$, LSD test for Tb.Th; Fig 3).

EA reverses elevated levels of IL-1β and TNF-α in OVX rats

Since the activation of osteoclast function induced by OVX is largely dependent on the release of inflammatory mediators, it would be important to measure the serum levels of inflammatory cytokines in the rats treated with EA. As shown in Fig 5, the levels of IL-1β and TNF-α in OVX rats were hightest among groups. Treatment with E2 or EA prevented this alteration in the OVX rats ($F_{(5, 54)} = 9.882$, $p < 0.01$, Dunnett's T3 test for IL-1β; $F_{(5, 54)} = 40.883$, $p < 0.01$, Dunnett's T3 test for TNF-α; Fig 5).

Discussion

The present study was designed to evaluate the potential effects of EA on osteoporosis induced by estrogen deficiency. Administration of EA was found to improve the maximum stress and Young's modulus of femur in OVX rats. Micro-computed tomography analysis revealed that EA could improve the trabecular architecture, as shown by increasing the BV/TV, Tb.N, and Tb.Th in OVX rats. However, EA did not affect the body weight and uterine weight. Our data suggest that EA is a potential candidate or a leading compound for anti-osteoporosis.

Recently, significant attention has been focused on the possible antiosteoporosis role of terpenoids. Loquat leaves, which are rich in triterpone, have been shown to suppress the OVX-induced bone mineral density deterioration, and ursolic acid was isolated through bioactivity-

Fig 3. Effects of EA on the BMD and trabecular architecture. Effects of E2 and EA on BMD (A), trabecular number (Tb.N) (B), trabecular thickness (Tb.Th) (C), trabecular separation (Tb.Sp) (D), structure model index (SIM) (E), ratio of trabecular volume/bone total volume (F). E2 (25 µg/kg/day); EA-L (1 mg/kg/day); EA-M (5 mg/kg/day), EA-H (15 mg/kg/day). n = 10; *$p < 0.05$, **$p < 0.01$ vs OVX; ## $p < 0.01$ vs Sham.

guided fractionation [32]. A previous study confirmed that ursolic acid could stimulate osteo-blast differentiation *in vitro* and induce new bone formation in a mouse calvarial bone forma-tion model [14]. Series of ursolic acid derivatives targeted for bone anabolic were synthesized, wherein one was found to improve the bone microarchitecture without estrogenic side effects in OVX rats [33]. Oleanolic acid is the isomer of ursolic acid. Oleanolic acid and its glycosides have been reported to prevent bone loss [13]. Quinoxaline derivative of oleanolic acid could also inhibit the osteoclastic bone resorption and prevent the OVX-induced bone loss [15]. EA shares a similar structure with oleanolic acid.

In this study, EA was systematically investigated on its protection against OVX-induced bone loss for the first time. An ideal drug to treat bone fragility should improve the extrinsic

Fig 4. 3-D architecture of trabecula bone. Representative micro-computed tomography samples within the distal metaphyseal femur region from Sham **(A)**, OVX **(B)**, E2(25 µg/kg/day) **(C)**, EA-M (5 mg/kg/day) **(D)**, and EA (15 mg/kg/day) treatment **(E)** rats.

biomechanical properties of bone, but at least not substantially impair the intrinsic properties [34]. Our results showed that EA at higher doses (5 mg/kg/day and 15 mg/kg/day) could prevent the OVX-induced decrease of elastic modulus and ultimate stress at the evaluated femur, but extrinsic biomechanical properties of the bone was not significantly improved. Recently, similar results were observed when treating the OVX rats with total lignans from the barks of *Eucommia ulmoides* [35,36].

The improvement of the intrinsic and extrinsic properties at the same time is difficult. For instance, fluoride can improve the bone mass [36], but fluoride incorporation into bone mineral reduce the intrinsic biomechanical properties [37]. Bone turnover is activated in osteoporosis, hence several bone metabolic biomarkers in serum or urine were evaluated. As expected, the OVX resulted in an increase in the bone turnover markers, as indicated by statistical significance in U-Ca, U-P, ALP, OC and DPD/Cr between OVX group and Sham group. However, previous studies report OC concentrations are not significantly higher in OVX group [26]. No significantly differences were observed concerning S-Ca and S-P in the study conducted by Zhang, while Shen found statistically higher levels of S-Ca in another study [25,26]. These slight differences among different studies might be related to the age of the animal used and the experimental period. EA showed osteoprotective effects in a dose-dependent manner. It had little effects at lower dose of 1 mg/kg/day, but prevented the alteration in serum ALP and OC, urinary Ca excretion, and DPD/Cr ratio at higher doses (5 mg/kg/day or 15 mg/kg/day). EA at higher doses prevented lower levels of BMD induced by OVX. BMD has been described as a major determinant of bone strength [38], however, it is insufficient to accurately predict the fracture risk and other parameters such as trabecular architecture should be considered in

Fig 5. Effects of EA on IL-1β and TNF-α in rat serum. Effects of E2 and EA on serum IL-1β **(A)** and TNF-α **(B)**. E2 (25 μg/kg/day); EA-L (1 mg/kg/day); EA-M (5 mg/kg/day), EA-H (15 mg/kg/day). n = 10; *$p < 0.05$, **$p < 0.01$ vs OVX; ##$p < 0.01$ vs Sham.

doi:10.1371/journal.pone.0136572.g005

evaluating the impact of a treatment on bone strength [39]. Therefore, micro-computed tomography was used further to evaluate the morphology and structure of the trabecular bone. EA (15 mg/kg/day) treatment markedly reversed the alterations of trabecular BV/TV, Tb.N, Tb.Th, SMI and Tb.Sp, indicating the beneficial effects of EA on trabecular bone architecture.

Pro-infammatory cytokines (IL-1β, IL-6, IL-8 and TNF-α) play an important role in regulating bone resorption, while estrogen deficiency always leads to remarkable increase in pro-iflammatory cytokines [2]. In the study, the serum levels of IL-1β and TNF-α were much higher in OVX group, which is consistent with other studies [40,41]. EA has been shown to display an anti-inflammatory effect in different models of chronic inflammation in mice through the down-regulation of pro-inflammatory cytokines such as IL-1β, IL-18, TNF-α [16,17,18]. Therefore, we proposed that anti-osteoporosis effect of EA might be relevant with its anti-inflammatory effects. Our results demonstrated that EA (5 and 15 mg/kg) could significantly reverse the levels of IL-1β and TNF-α, but only EA (15 mg/kg) could improve the trabecular architecture. It is suggested that osteoprotective effects of EA partly contribute to its anti-inflammatory effects.

In conclusion, EA administration has the potential to improve the cancellous bone structure and biochemical properties in OVX rats without side effect on the uterus. It may serve as a new candidate or a leading compound for the development of antiosteoporosis drug. Although the preliminary results indicated the osteoprotective effects of EA partly contributed to its anti-inflammatory effects, the mechanisms of EA on osteoporosis are far to understand.

The limitation of this study is the age of animals used. Three-month-old female Sprague–Dawley rats are not old enough to mimic the osteoporosis in the aged animals. The three months of experimental period would not be considered as long-term for bone turnover. It might be possible that the effects of EA treatment for younger OVX rats exhibited more variance in present study.

Acknowledgments

Author Contributions

Conceived and designed the experiments: GL MGZ. Performed the experiments: YTD WBK. Analyzed the data: JNZ. Contributed reagents/materials/analysis tools: JNZ. Wrote the paper: MGZ.

References

1. McNamara LM. Perspective on post-menopausal osteoporosis: establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fractures. J R Soc Interface. 2010; 7: 353–372. doi: 10.1098/rsif.2009.0282 PMID: 19846441

2. Al-Daghri NM, Yakout S, Al-Shehri E, Al-Fawaz H, Aljohani N, Al-Saleh Y. Inflammatory and bone turnover markers in relation to PTH and vitamin D status among Saudi postmenopausal women with and without osteoporosis. Int J Clin Exp Med. 2014; 7: 2812–2819. PMID: 25356143

3. Al-Daghri NM, Yakout S, Al-Shehri E, Al-Fawaz HA, Aljohani N, Al-Saleh Y. Inflammatory and bone turnover markers in relation to PTH and vitamin D status among saudi postmenopausal women with and without osteoporosis. Int J Clin Exp Med. 2014; 7: 3528–3535. PMID: 25419393

4. Leung F, Lau TW, To M, Luk KD, Kung AW. Atypical femoral diaphyseal and subtrochanteric fractures and their association with bisphosphonates. BMJ Case Rep. 2009;2009.

5. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008; 22: 346–350. doi: 10.1097/BOT.0b013e318172841c PMID: 18448990

6. Wang ZQ, Li JL, Sun YL, Yao M, Gao J, Yang Z, et al. Chinese herbal medicine for osteoporosis: a systematic review of randomized controlled trails. Evid Based Complement Alternat Med 2013; 2013: 356260. doi: 10.1155/2013/356260 PMID: 23431336

7. Chiba H, Uehara M, Wu J, Wang X, Masuyama R, Suzuki K, et al. Hesperidin, a citrus flavonoid, inhibits bone loss and decreases serum and hepatic lipids in ovariectomized mice. J Nutr. 2003; 133: 1892–1897. PMID: 12771335

8. Kim TH, Jung JW, Ha BG, Hong JM, Park EK, Kim HJ, et al. The effects of luteolin on osteoclast differentiation, function in vitro and ovariectomy-induced bone loss. J Nutr Biochem. 2011; 22: 8–15. doi: 10.1016/j.jnutbio.2009.11.002 PMID: 20233653

9. Li N, Jiang Y, Wooley PH, Xu Z, Yang SY. Naringin promotes osteoblast differentiation and effectively reverses ovariectomy-associated osteoporosis. J Orthop Sci. 2013; 18: 478–485. doi: 10.1007/s00776-013-0362-9 PMID: 23553541

10. Lim DW, Kim JG, Kim YT. Effects of dietary isoflavones from Puerariae radix on lipid and bone metabolism in ovariectomized rats. Nutrients. 2013; 5: 2734–2746. doi: 10.3390/nu5072734 PMID: 23867712

11. Moriwaki S, Suzuki K, Muramatsu M, Nomura A, Inoue F, Into T, et al. Delphinidin, one of the major anthocyanidins, prevents bone loss through the inhibition of excessive osteoclastogenesis in osteoporosis model mice. PLoS One. 2014; 9: e97177. doi: 10.1371/journal.pone.0097177 PMID: 24824988

12. Tsuji M, Yamamoto H, Sato T, Mizuha Y, Kawai Y, Taketani Y, et al. Dietary quercetin inhibits bone loss without effect on the uterus in ovariectomized mice. J Bone Miner Metab. 2009; 27: 673–681. doi: 10.1007/s00774-009-0088-0 PMID: 19495926

13. Bian Q, Liu SF, Huang JH, Yang Z, Tang DZ, Zhou Q, et al. Oleanolic acid exerts an osteoprotective effect in ovariectomy-induced osteoporotic rats and stimulates the osteoblastic differentiation of bone mesenchymal stem cells in vitro. Menopause. 2012; 19: 225–233. doi: 10.1097/gme.0b013e3182272ef1 PMID: 22011754

14. Lee SU, Park SJ, Kwak HB, Oh J, Min YK, Kim SH. Anabolic activity of ursolic acid in bone: Stimulating osteoblast differentiation in vitro and inducing new bone formation in vivo. Pharmacol Res. 2008; 58: 290–296. doi: 10.1016/j.phrs.2008.08.008 PMID: 18822379

15. Zhao Y, Huai Y, Jin J, Geng M, Li JX. Quinoxaline derivative of oleanolic acid inhibits osteoclastic bone resorption and prevents ovariectomy-induced bone loss. Menopause. 2011; 18: 690–697. doi: 10.1097/gme.0b013e3181fd7f4b PMID: 21228726

16. Joh EH, Gu W, Kim DH. Echinocystic acid ameliorates lung inflammation in mice and alveolar macrophages by inhibiting the binding of LPS to TLR4 in NF-kappaB and MAPK pathways. Biochem Pharmacol. 2012; 84: 331–340. doi: 10.1016/j.bcp.2012.04.020 PMID: 22564908

17. Joh EH, Jeong JJ, Kim DH. Inhibitory effect of echinocystic acid on 12-O-tetradecanoylphorbol-13-acetate-induced dermatitis in mice. Arch Pharm Res. 2014; 37: 225–231. doi: 10.1007/s12272-013-0092-8 PMID: 23515933

18. Ryu S, Shin JS, Jung JY, Cho YW, Kim SJ, Jang DS, et al. Echinocystic acid isolated from Eclipta prostrata suppresses lipopolysaccharide-induced iNOS, TNF-alpha, and IL-6 expressions via NF-kappaB inactivation in RAW 264.7 macrophages. Planta Med. 2013; 79: 1031–1037. doi: 10.1055/s-0032-1328767 PMID: 23877917

19. Wang H, Wang Q, Xiao SL, Yu F, Ye M, Zheng YX, et al. Elucidation of the pharmacophore of echinocystic acid, a new lead for blocking HCV entry. Eur J Med Chem. 2013; 64: 160–168. doi: 10.1016/j.ejmech.2013.03.041 PMID: 23644199

20. Tong X, Lin S, Fujii M, Hou DX. Echinocystic acid induces apoptosis in HL-60 cells through mitochondria-mediated death pathway. Cancer Lett. 2004; 212: 21–32. PMID: 15246558

21. Wu J, Li J, Zhu Z, Huang G, Tang Y, Gao X. Protective effects of echinocystic acid isolated from Gleditsia sinensis Lam. against acute myocardial ischemia. Fitoterapia. 2010; 81: 8–10. doi: 10.1016/j.fitote.2009.06.015 PMID: 19573579

22. Min C. The Study of Antiosteoporotic Effects and Mechanisms of EZW, Fructus Ligustri Lucidi and Herba Ecliptae on Osteoporosis. xi'an: Northwest University. 2010.

23. Wang Q, Wang Y, Deng Y, Shi T, Liu X, Zhou D. A rapid determination of drug candidate tyrosol galactoside in rat plasma by HPLC and its application to the pharmacokinetics study. Eur J Drug Metab Pharmacokinet. 2011; 35: 131–136. doi: 10.1007/s13318-010-0015-8 PMID: 21302040

24. Turner CH, Burr DB. Basic biomechanical measurements of bone: a tutorial. Bone. 1993; 14: 595–608. PMID: 8274302

25. Shen Y, Li YQ, Li SP, Ma L, Ding LJ, Ji H. Alleviation of ovariectomy-induced osteoporosis in rats by Panax notoginseng saponins. J Nat Med. 2010; 64: 336–345. doi: 10.1007/s11418-010-0416-7 PMID: 20376572

26. Zhang R, Liu ZG, Li C, Hu SJ, Liu L, Wang JP, et al. Du-Zhong (Eucommia ulmoides Oliv.) cortex extract prevent OVX-induced osteoporosis in rats. Bone. 2009; 45: 553–559. doi: 10.1016/j.bone.2008.08.127 PMID: 18835589

27. Liu SB, Zhao R, Li XS, Guo HJ, Tian Z, Zhang N, et al. Attenuation of reserpine-induced pain/depression dyad by gentiopicroside through downregulation of GluN2B receptors in the amygdala of mice. Neuromolecular Med. 2014; 16: 350–359. doi: 10.1007/s12017-013-8280-8 PMID: 24584520

28. Bhattacharya A, Rahman M, Sun D, Fernandes G. Effect of fish oil on bone mineral density in aging C57BL/6 female mice. J Nutr Biochem. 2007; 18: 372–379. PMID: 16963250

29. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193: 265–275. PMID: 14907713

30. Chan BY, Lau KS, Jiang B, Kennelly EJ, Kronenberg F, Kung AW. Ethanolic extract of Actaea racemosa (black cohosh) potentiates bone nodule formation in MC3T3-E1 preosteoblast cells. Bone. 2008; 43: 567–573. doi: 10.1016/j.bone.2008.04.018 PMID: 18555764

31. Davicco MJ, Remond B, Jabet S, Barlet JP. Plasma osteocalcin concentrations in cows around parturition. The influence of a regular versus a very short dry period. Reprod Nutr Dev. 1992; 32: 313–319. PMID: 1418393

32. Tan H, Furuta S, Nagata T, Ohnuki K, Akasaka T, Shirouchi B, et al. Inhibitory effects of the leaves of loquat (Eriobotrya japonica) on bone mineral density loss in ovariectomized mice and osteoclast differentiation. J Agric Food Chem. 2014; 62: 836–841. doi: 10.1021/jf402735u PMID: 24404864

33. Fu HJ, Zhou YR, Bao BH, Jia MX, Zhao Y, Zhang L, et al. Tryptophan hydroxylase 1 (Tph-1)-targeted bone anabolic agents for osteoporosis. J Med Chem. 2014; 57: 4692–4709. doi: 10.1021/jm5002293 PMID: 24844139

34. Liu ZG, Zhang R, Li C, Ma X, Liu L, Wang JP, et al. The osteoprotective effect of Radix Dipsaci extract in ovariectomized rats. J Ethnopharmacol. 2009; 123: 74–81. doi: 10.1016/j.jep.2009.02.025 PMID: 19429343

35. Zhang R, Pan YL, Hu SJ, Kong XH, Juan W, Mei QB. Effects of total lignans from Eucommia ulmoides barks prevent bone loss in vivo and in vitro. J Ethnopharmacol. 2014; 155: 104–112. doi: 10.1016/j.jep.2014.04.031 PMID: 24786573

36. Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med. 1990; 322: 802–809. PMID: 2407957

37. Turner CH, Hasegawa K, Zhang W, Wilson M, Li Y, Dunipace AJ. Fluoride reduces bone strength in older rats. J Dent Res. 1995; 74: 1475–1481. PMID: 7560402

38. Bouxsein ML. Mechanisms of osteoporosis therapy: a bone strength perspective. Clin Cornerstone. 2003;Suppl 2: : S13–21. PMID: 15035555

39. Devareddy L, Khalil DA, Smith BJ, Lucas EA, Soung do Y, Marlow DD, et al. Soy moderately improves microstructural properties without affecting bone mass in an ovariectomized rat model of osteoporosis. Bone. 2006; 38: 686–693. PMID: 16406762

40. Polat B, Halici Z, Cadirci E, Albayrak A, Karakus E, Bayir Y, et al. The effect of alpha-lipoic acid in ovariectomy and inflammation-mediated osteoporosis on the skeletal status of rat bone. Eur J Pharmacol. 2013; 718: 469–474. doi: 10.1016/j.ejphar.2013.07.033 PMID: 23911880

41. Abuohashish HM, Ahmed MM, Al-Rejaie SS, Eltahir KE. The antidepressant bupropion exerts alleviating properties in an ovariectomized osteoporotic rat model. Acta Pharmacol Sin. 2015; 36: 209–220. doi: 10.1038/aps.2014.111 PMID: 25544359